maulik963
☆    

India,
2016-05-31 10:09
(3681 d 12:36 ago)

Posting: # 16372
Views: 4,936
 

 Partial AUC & Cmax in case of multiphasic modified release drug product [Regulatives / Guidelines]

Dear All,

I wish to conduct a 2-way crossover study on multiphasic modified release drug product for EMEA submission.

The drug product is a prolonged release formulation with biphasic release pattern (IR+MR). The initial maximum concentration achieves at about 1 to 2 hours (due to release of IR Part) and Peak plasma concentration achieves at about 6 to 8 hours.

As per "Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms_Jun-2015", For single dose study of multiphasic modified release drug product following parameters has to show bioequivalence.
AUC0-t, AUC0-∞, partialAUCs and Cmax in all phases.

I have kept AUC0-t, AUC0-∞, partialAUC0-2, partialAUC2-t.

Please provide your opinion on following points.

(1) Please help to understand the meaning of "Cmax in all phases".
Shall I consider it as Cmax(0-2) & Cmax(2-t)? OR shall I consider Cmax(0-t)?
Shall I report the result for Cmax(0-2) & Cmax(2-t) and prove bioequivalence only on Cmax(0-t)?

(2) As per the guideline, Cmax(x+1) and partialAUC(x+1) also need to be evaluated. In this case shall I consider it as Cmax(2+1) = Cmax0-3 & partialAUC(2+1) = partialAUC(0-3)? Please help to understand the rationale of Cmax(x+1) & partialAUC(x+1).

Thanks in advance.
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2016-05-31 15:14
(3681 d 07:31 ago)

@ maulik963
Posting: # 16373
Views: 4,017
 

 The x unveiled

Hi Maulik,

❝ The drug product is a prolonged release formulation with biphasic release pattern (IR+MR). The initial maximum concentration achieves at about 1 to 2 hours (due to release of IR Part) and Peak plasma concentration achieves at about 6 to 8 hours.


❝ […] For single dose study of multiphasic modified release drug product following parameters has to show bioequivalence.

❝ AUC0-t, AUC0-∞, partialAUCs and Cmax in all phases.

❝ I have kept AUC0-t, AUC0-∞, partialAUC0-2, partialAUC2-t.


Correct.

❝ (1) Please help to understand the meaning of "Cmax in all phases".

❝ Shall I consider it as Cmax(0-2) & Cmax(2-t)?


Yes. Pre-specified cut-off time 2 hours. Hence, 1st phase ≤2 hours and 2nd phase >2 hours. You have to demonstrate BE for both.

❝ (2) As per the guideline, Cmax(x+1) and partialAUC(x+1) also need to be evaluated. In this case shall I consider it as Cmax(2+1) = Cmax0-3 & partialAUC(2+1) = partialAUC(0-3)?


No. The “x” in the table of Section 6.8.2.1 is an index denoting the phase – not a time point. In your case: Cmax(1) = Cmax(0–2), Cmax(2) = Cmax(2–t), partialAUC(1) = partialAUC0–2, partialAUC(2) = partialAUC2–t – exactly as you correctly guessed in the beginning of your post.

For most biphasic products the first phase is critical in terms of variability. Consider reference-scaling (both Cmax and partial AUC).

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
maulik963
☆    

India,
2016-06-02 15:45
(3679 d 07:00 ago)

@ Helmut
Posting: # 16380
Views: 3,849
 

 The x unveiled

Dear Helmut,

Thanks for the reply. As I understood, Cmax(x) denotes for an Immediate release phase of the formulation and Cmax(x+1) denotes for the modified release phase of the formulation. Please correct if I am wrong.

In addition to Cmax(0-2) & Cmax(2-t), shall I consider Cmax(total) [i.e. Cmax(0-t)] to demonstrate BE?

Based on the above discussion shall I keep below PK parameters to demonstrate BE?
AUC0-t, AUC0-∞, partialAUC(0-2), partialAUC(2-t), Cmax(0-2), Cmax(2-t) & Cmax(0-t).
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2016-06-02 16:07
(3679 d 06:38 ago)

@ maulik963
Posting: # 16381
Views: 3,951
 

 Biphasic: x=2

Hi Maulik,

❝ As I understood, Cmax(x) denotes for an Immediate release phase of the formulation and Cmax(x+1) denotes for the modified release phase of the formulation.


In your case (biphasic), yes. The guideline deals with multiphasic formulations. Hhence, x>2 is possible.

❝ In addition to Cmax(0-2) & Cmax(2-t), shall I consider Cmax(total) [i.e. Cmax(0-t)] to demonstrate BE?


No. In my studies I only reported it.

❝ Based on the above discussion shall I keep below PK parameters to demonstrate BE?

❝ AUC0-t, AUC0-∞, partialAUC(0-2), partialAUC(2-t), Cmax(0-2), Cmax(2-t) & Cmax(0-t).


Exactly. Good luck for demonstrating BE of seven PK-metrics…


PS: If you crosspost (e.g., to David’s PKPD-list) link to this thread as well. Helps others “over there” to see what’s going on.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
223 visitors (0 registered, 223 guests [including 19 identified bots]).
Forum time: 22:46 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5